Prof. DDr. Markus JörgerVeröffentlicht am: 24. Okt. 2018
ESMO 2018: An oral FGFR inhibitor for head and neck cancer
PD DDr. Markus Jörger, Department for Medical Oncology and Hematology of Kantonsspital St.Gallen on a phase I trial investigating the treatment of head and neck cancer with rogaratinib, an oral FGFR inhibitor.
